Knome has raised $13 million in funding led by current investors. This round of funding will be used for promoting growth and expansion of their genomic services and software systems. Knome was founded in 2007 in Cambridge, Massachusetts.
Knome is a pioneer in next generation sequencing (NGS) genomic data. Knome uses their bioinformatics expertise and a proprietary technology platform across over 130 projects for biopharmaceutical companies and academic institutions.
?We see a great need for our products in commercial and academic clinical labs adopting NGS technology in their move into precision medicine,? stated Knome CEO Wolfgang Daum. ?The knoSYS provides a secure, fast computing environment behind the customer?s firewall, while knoSOFT encapsulates the lab?s expertise and access to the public and institutional knowledge needed to provide the timely, reproducible, high quality services their customers require.?